Meridian Bioscience, Inc. (VIVO) Tops Q2 EPS by 2c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.87 +7.71%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- MP Materials seen largely insulated after China export-control move
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
